truth about semaglutide and other GLP-1 weight-loss drugs are transforming bodies, but they’re also triggering thousands of adverse medical reports and major lawsuits. This episode uncovers alarming risks linked Compounded "semaglutide" is not FDA-approved

Peter Attia 18 Feb 23 Lean mass loss on GLP-1 receptor agonists: a downside of the miracle drugs Clinical trials have generated impressive data on the effects of GLP-1 agonists on body weight and BMI, but how do these drugs perform in terms of body composition

Conflict of interest: RJS is employed by Eli Lilly

Underlying GI conditions (and side effects like sulfur burps) are often exacerbated by FODMAPs, types of carbohydrates that digest poorly in the small intestine

PSCI prevalence ranged from 17.5% at 28 days to 89% at 7 years with considerable variance in type and timing of assessment

Prompt medical attention may be needed for severe abdominal pain, repeated vomiting, signs of dehydration, fainting, allergic reactions, or symptoms that feel unusual or concerning